
According to data from Benzinga Pro, during Q1, Reshape Lifesciences's (NASDAQ:RSLS) reported sales totaled $2.44 million. Despite a 76.83% increase in earnings, the company posted a loss of $8.21 million. Reshape Lifesciences collected $3.14 million in revenue during Q4, but reported earnings showed a $35.46 million loss.